Wall Street analysts expect Entellus Medical, Inc. (NASDAQ:ENTL) to report earnings of ($0.39) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Entellus Medical’s earnings. The lowest EPS estimate is ($0.45) and the highest is ($0.36). Entellus Medical reported earnings of ($0.50) per share in the same quarter last year, which suggests a positive year over year growth rate of 22%. The business is expected to issue its next quarterly earnings report on Thursday, November 2nd.

According to Zacks, analysts expect that Entellus Medical will report full-year earnings of ($1.39) per share for the current fiscal year, with EPS estimates ranging from ($1.44) to ($1.34). For the next financial year, analysts forecast that the firm will report earnings of ($0.86) per share, with EPS estimates ranging from ($0.94) to ($0.76). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Entellus Medical.

Entellus Medical (NASDAQ:ENTL) last announced its quarterly earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.03. Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 66.04%. The firm had revenue of $22.10 million for the quarter, compared to the consensus estimate of $21.87 million. During the same period in the previous year, the company posted ($0.27) earnings per share. Entellus Medical’s quarterly revenue was up 18.0% on a year-over-year basis.

A number of research analysts have commented on the company. BidaskClub raised Entellus Medical from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 14th. Zacks Investment Research raised Entellus Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Entellus Medical in a research report on Wednesday, July 12th. Canaccord Genuity lowered Entellus Medical from a “buy” rating to a “hold” rating and cut their price objective for the stock from $22.00 to $18.00 in a research report on Thursday, May 4th. Finally, ValuEngine raised Entellus Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $21.83.

In other Entellus Medical news, CFO Brent Moen bought 6,100 shares of the firm’s stock in a transaction dated Monday, May 8th. The stock was acquired at an average price of $12.21 per share, for a total transaction of $74,481.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert S. White bought 10,000 shares of the firm’s stock in a transaction dated Monday, May 8th. The shares were acquired at an average price of $12.24 per share, with a total value of $122,400.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 17,700 shares of company stock worth $216,625. Corporate insiders own 9.10% of the company’s stock.

Several large investors have recently made changes to their positions in ENTL. State Street Corp increased its stake in shares of Entellus Medical by 8.5% in the fourth quarter. State Street Corp now owns 105,783 shares of the medical technology company’s stock worth $2,007,000 after buying an additional 8,251 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Entellus Medical by 23.1% in the fourth quarter. Renaissance Technologies LLC now owns 78,800 shares of the medical technology company’s stock worth $1,495,000 after buying an additional 14,800 shares during the last quarter. Perkins Capital Management Inc. increased its stake in shares of Entellus Medical by 6.5% in the first quarter. Perkins Capital Management Inc. now owns 60,017 shares of the medical technology company’s stock worth $828,000 after buying an additional 3,667 shares during the last quarter. Eqis Capital Management Inc. increased its stake in shares of Entellus Medical by 22.8% in the first quarter. Eqis Capital Management Inc. now owns 33,475 shares of the medical technology company’s stock worth $462,000 after buying an additional 6,223 shares during the last quarter. Finally, Swiss National Bank increased its stake in shares of Entellus Medical by 98.9% in the first quarter. Swiss National Bank now owns 17,700 shares of the medical technology company’s stock worth $244,000 after buying an additional 8,800 shares during the last quarter. Institutional investors and hedge funds own 76.10% of the company’s stock.

WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/06/entellus-medical-inc-entl-expected-to-post-earnings-of-0-39-per-share.html.

Shares of Entellus Medical (NASDAQ:ENTL) traded down 2.20% during midday trading on Friday, hitting $16.44. The stock had a trading volume of 280,197 shares. The firm’s 50 day moving average price is $16.33 and its 200 day moving average price is $15.03. The firm’s market cap is $360.30 million. Entellus Medical has a 52-week low of $11.47 and a 52-week high of $22.63.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Get a free copy of the Zacks research report on Entellus Medical (ENTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.